The psychiatric side-effects of rimonabant

Revista Brasileira de Psiquiatria

Volumn 31, Issue 2, 2009, Pages 145-153

  Moreira, Fabrício A ^a   Crippa, José Alexandre S ^b,c  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Fellow of the National Research Council   (Brazil)

Author keywords

Anxiety; Cannabinoids; Depression; Drug effects; Obesity

Indexed keywords

CANNABINOID 1 RECEPTOR; CP 945598; ENDOCANNABINOID; HALOPERIDOL; NEUROKININ 3 RECEPTOR ANTAGONIST; NEUROTENSIN RECEPTOR ANTAGONIST; NICOTINE PATCH; PLACEBO; RIMONABANT; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C ANTAGONIST; TARANABANT;

ANXIETY; ARTICLE; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; INSOMNIA; IRRITABILITY; LOW CALORY DIET; MENTAL DISEASE; METABOLIC DISORDER; MONOTHERAPY; MOOD CHANGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANIC; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SMOKING CESSATION; STRESS; TOBACCO DEPENDENCE; WEIGHT REDUCTION;

ANXIETY DISORDERS; APPETITE DEPRESSANTS; DEPRESSIVE DISORDER; ENDOCANNABINOIDS; HUMANS; METABOLIC DISEASES; OBESITY; PIPERIDINES; PLACEBO EFFECT; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, CANNABINOID, CB1; SMOKING; SMOKING CESSATION;

EID: 67650504086     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-44462009000200012     Document Type: Article

References (65)

1. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365(9468):1389-1397 (Pubitemid 40523733)
2. Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353(20): 2121-2134
3. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RiO-North America: a randomized controlled trial. JAMA. 2006;295(7):761-775 (Pubitemid 43244304)
4. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006;368(9548):1660-1672 (Pubitemid 46048528)
5. Van Gaal LF, Scheen AJ, Rissanen AM, Rössner S, Hanotin C, Ziegler O; RIO-Europe Study Group. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur Heart J. 2008;29(14):1761-1771 (Pubitemid 352019811)
6. Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Després JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM; STRADIVARIUS Investigators. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA. 2008;299(13):1547-1560
7. Rigotti NA, Gonzales D, Dale LC, Lawrence D, Chang Y; CIRRUS Study Group. A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. Addiction. 2009;104(2):266-276
8. Rimonabant Briefing Document: Endocrine and Metabolic Drugs Advisory Committee Meeting: NDA 21-888. US Food and Drug Administration [cited 2009 Feb 18]. Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007- 4306b1-fdabackgrounder. pdf.
9. Sanofi-Aventis. Accomplia update [cited 2008 nov 9]. Available from: http://en.sanofi-aventis.com/investors/events/corporate/2008/ 081023-investor-update.asp.
10. Mechoulam R, Devane Wa, Breuer A, Zahalka J. A random walk through a cannabis field. Pharmacol Biochem Behav. 1991;40(3):461-464
11. Murray RM, Morrison PD, Henquet C, Di Forti M. Cannabis, the mind and society: the hash realities. Nat Rev Neurosci. 2007;8(11):885-895 (Pubitemid 350006219)
12. Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr. 2006;28(2):153-157
13. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54(2):161-202. (Pubitemid 34575709)
14. Marsicano G, Lutz B. Neuromodulatory functions of the endocannabinoid system. J Endocrinol Invest. 2006;29(3 Suppl):27-46.
15. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003;4(11):873-884 (Pubitemid 37351427)
16. Herkenham M, Lynn AB, Little Md, Johnson MR, Melvin LS, de Costa BR, Rice KC. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990;87(5):1932-1936
17. Hall W, Solowij N. Adverse effects of cannabis. Lancet. 1998;352(9140):1611-1616
18. Hohmann AG, Suplita RL 2nd. Endocannabinoid mechanisms of pain modulation. AAPS J. 2006;8(4):E693-708.
19. Kunos G. Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system? Am J Med. 2007;120(9 Suppl 1):S18-24. (Pubitemid 47284984)
20. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 2006;27(1):73-100. (Pubitemid 43228239)
21. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994;350(2-3):240-244 (Pubitemid 24268029)
22. Rinaldi-Carmona M, Barth F, Héaulme M, Alonso R, Shire D, Congy C, Soubrié P, Brelière JC, Le Fur G. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 1995;56(23-24):1941-1947
23. Huestis Ma, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Frank RA. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry. 2001;58(4):322-328 (Pubitemid 32299527)
24. Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI. SR141716A is an inverse agonist at the human CB1 cannabinoid receptor. Eur J Pharmacol. 1997;334(1):R1-R2. (Pubitemid 27417820)
25. Moreira FA, Lutz B. The endocannabinoid system: emotion, learning and addiction. Addict Biol. 2008;13(2):196-212. (Pubitemid 351698889)
26. Crippa JA, Lacerda AL, Amaro E, Busatto Filho G, Zuardi AW, Bressan RA. Brain effects of cannabis - neuroimaging findings. Rev Bras Psiquiatr. 2005;27(1):70-78 (Pubitemid 40477458)
27. van der Staay FJ Animal models of behavioral dysfunctions: basic concepts and classifications, and an evaluation strategy. Brain Res Rev. 2006;52(1):131-159 (Pubitemid 44069577)
28. Berrendero F, Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl). 2002;163(1):111-117 (Pubitemid 34985320)
29. Onaivi ES, Green MR, Martin BR. Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther. 1990;253(3):1002-1009 (Pubitemid 20209356)
30. Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther. 2006;318(1):304-311 (Pubitemid 43920770)
31. Rubino T, Sala M, Viganò D, Braida D, Castiglioni C, Limonta V, Guidali C, Realini N, Parolaro D. Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral delta9-tetrahydrocannabinol in rats. Neuropsychopharmacology. 2007;32(9):2036-2045 (Pubitemid 47258523)
32. Hill MN, Gorzalka BB. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behav Pharmacol. 2005;16(5-6):333-352 (Pubitemid 41404805)
33. Musty RE, Bouldin MJ, Erickson JR, Deyo R. CBD and THC extracts alter Behavioral Despair on the Mouse Tail Suspension test. Asilomar Conference Center. In: Symposium on the Cannabinoids, Burlington, VT; 2002; International Cannabinoid Research Society; 140.
34. Bortolato M, Campolongo P, Mangieri RA, Scattoni ML, Frau R, trezza V, La Rana G, Russo R, Calignano A, Gessa GL, Cuomo V, Piomelli D. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology. 2006;31(12):2652-2659
35. Hill MN, Gorzalka BB. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol. 2005;15(6):593-599 (Pubitemid 41587409)
36. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med. 2003;9(1):76-81. (Pubitemid 36098263)
37. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, Tontini A, Tarzia G, Mor M, Trezza V, Goldberg SR, Cuomo V, Piomelli D. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A. 2005;102(51):18620-18625 (Pubitemid 43011275)
38. Moreira FA, Kaiser N, Monory K, Lutz B. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid- degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology. 2008;54(1):141-150 (Pubitemid 350299416)
39. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl). 2002;159(4):379-387 (Pubitemid 34143362)
40. Navarro M, Hernández E, Muñoz RM, del Arco I, Villanúa Ma, Carrera MR, Rodríguez de Fonseca F. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport. 1997;8(2):491-496 (Pubitemid 27180108)
41. Steiner Ma, Wanisch K, Monory K, Marsicano G, Borroni E, Bächli H, Holsboer F, Lutz B, Wotjak CT. Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. Pharmacogenomics J. 2008;8(3):196-208. (Pubitemid 351712644)
42. Marsicano G, Wotjak Ct, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgänsberger W, Di Marzo V, Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418(6897):530-534 (Pubitemid 34851398)
43. Meltzer HY, Arvanitis L, Bauer D, Rein W; Meta-Trial Study Group. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry. 2004;161(6):975-984 (Pubitemid 38735983)
44. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-370
45. Dixon JB, Dixon ME, O'Brien PE. Depression in association with severe obesity: changes with weight loss. Arch Intern Med. 2003;163(17):2058-2065 (Pubitemid 37151248)
46. Onyike Cu, Crum RM, Lee HB, Lyketsos CG, Eaton WW. Is obesity associated with major depression? Results from the third national Health and nutrition Examination Survey. Am J Epidemiol. 2003;158(12):1139-1147 (Pubitemid 37548783)
47. US Food and Drug Administration Endocrinologic and Metabolic advisory. FDA Briefing Information - June 13, 2007. NDA 21-888 ZIMULTI (rimonabant) - Sanofi-Aventis [cited 2008 Jul 23]. Available from: http://www.fda.gov/ohrms/ dockets/ac/07/briefing/2007-4306b1-fda-backgrounder.pdf.
48. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007;370(9600):1706-1713 (Pubitemid 350100788)
49. Rucker D, Padwal R, LI SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335(7631):1194-1199 (Pubitemid 350273303)
50. Van Gaal L, Pi-Sunyer X, Després JP, McCarthy C, Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care. 2008;31 Suppl 2:S229-40.
51. Rosenstock J, Hollander P, Chevalier S, Iranmanesh A; SERENADE Study Group. SERENAE: the Study Evaluating Rimonabant Efficacy in drug-naive diabetic patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care. 2008;31(11):2169-2176
52. Stapleton JA. Trial comes too late as psychiatric side effects end hope for rimonabant. Addiction. 2009;104(2):277-278
53. Després JP, Ross R, Boka G, Alméras N, Lemieux I; for the ADAGIO-Lipids Investigators. Effect of rimonabant on the high-triglyceride/low- HDL-cholesterol dyslipidemia, intra-abdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol. 2009;29(3):416-423
54. Addy C, LI S, Agrawal N, Stone J, Majumdar A, Zhong L, Li H, Yuan J, Maes A, Rothenberg P, Cote J, Rosko K, Cummings C, Warrington S, Boyce M, Gottesdiener K, Stoch A, Wagner J. Safety, Tolerability, parmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers. J Clin Pharmacol. 2008;48(4):418-427
55. Ady C, Rothenberg P, Li S, Majumdar A, Arawal N, Li H, Zhong L, Yuan J, Maes a, dunbar S, Cote J, Rosko K, Van Dyck K, De Lepeleire I, de Hoon J, Van Hecken A, Depré M, Knops A, Gottesdiener K, Stoch A, Wagner J. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. J Clin Pharmacol. 2008;48(6):734-744
56. Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, Lu K, Yuan J, Sanabria-Bohórquez SM, Stoch A, Stevens C, Fong TM, De Lepeleire I, Cilissen C, Cote J, Rosko K, Gendrano IN 3rd, Nguyen AM, Gumbiner B, Rothenberg P, de Hoon J, Bormans G, Depré M, Eng WS, Ravussin E, Klein S, Blundell J, Herman GA, Burns HD, Hargreaves RJ, Wagner J, Gottesdiener K, Amatruda JM, Heymsfield SB. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metabolism. 2008;7(1):68-78.
57. Moreira FA, Aguiar DC, Campos AC, Lisboa SF, Terzian AL, Resstel LB, Guimaraes FS. Antiaversive effects of cannabinoids: is the periaqueductal gray involved? Neural Plasticity. 2009; 2009:625469.
58. Bambico FR, Gobbi G. The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets. Expert Opin Ther Targets. 2008;12(11):1347-1366
59. Parolaro D, Rubino T. The role of the endogenous cannabinoid system in drug addiction. Drug News Perspect. 2008;21(3):149-157 (Pubitemid 351809138)
60. Di Marzo V. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists? Nat Clin Pract Cardiovasc Med. 2008;5(10):610-612
61. Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr. 2008;30(3):271-280
62. Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, Azevedo-Marques PM, Hallak JE, Mcguire PK, Filho Busatto G. Effects of cannabidiol (CBd) on regional cerebral blood flow. Neuropsychopharmacology. 2004;29(2):417-426 (Pubitemid 38175159)
63. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res. 2006;39(4):421-429
64. Weiss L, Zeira M, Reich S, Har-Noy M, Mechoulam R, Slavin S, Gallily R. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity. 2006;39(2):143-151 (Pubitemid 43675258)
65. Zuardi A, Crippa J, Hallak J, Pinto J, Chagas M, Rodrigues G, Dursun S, Tumas V. Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol. 2008 (in press).